0001593184 2026-01-01 2026-03-31 0001593184 2026-05-20 0001593184 2026-03-31 0001593184 2025-12-31 0001593184 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001593184 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001593184 2025-01-01 2025-03-31 0001593184 BRGX:OfficersDirectorsAndContractorsMember 2026-01-01 2026-03-31 0001593184 BRGX:OfficersDirectorsAndContractorsMember 2025-01-01 2025-03-31 0001593184 BRGX:RelatedPartyInterestMember 2026-01-01 2026-03-31 0001593184 BRGX:RelatedPartyInterestMember 2025-01-01 2025-03-31 0001593184 us-gaap:CommonStockMember 2024-12-31 0001593184 us-gaap:PreferredStockMember 2024-12-31 0001593184 BRGX:CommonStockIssuableMember 2024-12-31 0001593184 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001593184 us-gaap:RetainedEarningsMember 2024-12-31 0001593184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001593184 2024-12-31 0001593184 us-gaap:CommonStockMember 2025-12-31 0001593184 us-gaap:PreferredStockMember 2025-12-31 0001593184 BRGX:CommonStockIssuableMember 2025-12-31 0001593184 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001593184 us-gaap:RetainedEarningsMember 2025-12-31 0001593184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001593184 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001593184 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001593184 BRGX:CommonStockIssuableMember 2025-01-01 2025-03-31 0001593184 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001593184 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001593184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001593184 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001593184 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001593184 BRGX:CommonStockIssuableMember 2026-01-01 2026-03-31 0001593184 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001593184 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001593184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001593184 us-gaap:CommonStockMember 2025-03-31 0001593184 us-gaap:PreferredStockMember 2025-03-31 0001593184 BRGX:CommonStockIssuableMember 2025-03-31 0001593184 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001593184 us-gaap:RetainedEarningsMember 2025-03-31 0001593184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001593184 2025-03-31 0001593184 us-gaap:CommonStockMember 2026-03-31 0001593184 us-gaap:PreferredStockMember 2026-03-31 0001593184 BRGX:CommonStockIssuableMember 2026-03-31 0001593184 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001593184 us-gaap:RetainedEarningsMember 2026-03-31 0001593184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001593184 BRGX:CustomerAdvancesMember 2026-03-31 0001593184 BRGX:DeferredShipmentsMember 2026-03-31 0001593184 BRGX:CommissionsPayableMember 2026-03-31 0001593184 BRGX:CommissionsPayableMember 2025-12-31 0001593184 BRGX:OptionsAndWarrantsMember 2026-01-01 2026-03-31 0001593184 BRGX:MedicalTestingMember 2026-01-01 2026-03-31 0001593184 BRGX:MedicalTestingMember 2025-01-01 2025-03-31 0001593184 BRGX:WellnessDevicesMember 2026-01-01 2026-03-31 0001593184 BRGX:WellnessDevicesMember 2025-01-01 2025-03-31 0001593184 BRGX:NutritionalMember 2026-01-01 2026-03-31 0001593184 BRGX:NutritionalMember 2025-01-01 2025-03-31 0001593184 BRGX:OtherReturnsMember 2026-01-01 2026-03-31 0001593184 BRGX:OtherReturnsMember 2025-01-01 2025-03-31 0001593184 BRGX:MedicalAndAcademicMember 2026-01-01 2026-03-31 0001593184 BRGX:MedicalAndAcademicMember 2025-01-01 2025-03-31 0001593184 BRGX:CustomersAndDirectSalesMember 2026-01-01 2026-03-31 0001593184 BRGX:CustomersAndDirectSalesMember 2025-01-01 2025-03-31 0001593184 BRGX:ResellerMember 2026-01-01 2026-03-31 0001593184 BRGX:ResellerMember 2025-01-01 2025-03-31 0001593184 BRGX:MedicalTestingMember 2026-03-31 0001593184 BRGX:MedicalTestingMember 2025-12-31 0001593184 BRGX:WellnessDevicesMember 2026-03-31 0001593184 BRGX:WellnessDevicesMember 2025-12-31 0001593184 BRGX:NutritionalMember 2026-03-31 0001593184 BRGX:NutritionalMember 2025-12-31 0001593184 BRGX:TwoConsultantsMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001593184 BRGX:TwoConsultantsMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001593184 BRGX:TwoConsultantsMember us-gaap:CommonStockMember 2025-02-01 2025-02-28 0001593184 BRGX:ContractorsAndProfessionalMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001593184 BRGX:DirectorsAndAnOfficerMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001593184 BRGX:BoardMembersAndOfficersMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001593184 BRGX:TwoNoteHoldersMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001593184 2025-01-01 2025-12-31 0001593184 BRGX:StockOptionAndWarrantsMember 2025-12-31 0001593184 BRGX:StockOptionAndWarrantsMember 2026-01-01 2026-03-31 0001593184 BRGX:StockOptionAndWarrantsMember 2026-03-31 0001593184 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001593184 us-gaap:WarrantMember 2026-03-31 0001593184 BRGX:HowardNotesMember 2026-03-31 0001593184 BRGX:HowardNotesMember 2025-12-31 0001593184 BRGX:GoffNoteMember 2026-03-31 0001593184 BRGX:GoffNoteMember 2025-12-31 0001593184 BRGX:InsuranceNotesMember 2026-03-31 0001593184 BRGX:InsuranceNotesMember 2025-12-31 0001593184 BRGX:AlderNotesNetOfDiscountMember 2026-03-31 0001593184 BRGX:AlderNotesNetOfDiscountMember 2025-12-31 0001593184 BRGX:EIDLNotesMember 2026-03-31 0001593184 BRGX:EIDLNotesMember 2025-12-31 0001593184 BRGX:StripeCapitalMember 2026-03-31 0001593184 BRGX:StripeCapitalMember 2025-12-31 0001593184 BRGX:OtherNotesMember 2026-03-31 0001593184 BRGX:OtherNotesMember 2025-12-31 0001593184 BRGX:HowardNoteMember 2026-03-31 0001593184 BRGX:DocSunBiomedicalHoldingsIncMember BRGX:GenisisGlassNoteMember 2024-01-10 0001593184 BRGX:DocSunBiomedicalHoldingsIncMember BRGX:GenisisGlassNoteMember 2024-01-09 2024-01-10 0001593184 BRGX:GenisisGlassNoteMember 2025-10-09 0001593184 BRGX:GenisisGlassNoteMember 2025-10-08 2025-10-09 0001593184 BRGX:GenisisGlassNoteMember 2026-01-01 2026-03-31 0001593184 BRGX:EIDLLoanMember BRGX:SBALoan1Member 2026-03-31 0001593184 BRGX:EIDLLoanMember BRGX:SBALoan2Member 2025-12-31 0001593184 BRGX:EIDLLoanMember 2025-12-31 0001593184 BRGX:EIDLLoanMember 2026-03-31 0001593184 BRGX:StripeCapitalMember 2025-07-23 2025-07-24 0001593184 BRGX:StripeCapitalMember 2026-01-01 2026-03-31 0001593184 BRGX:RelatedPartyDebtsMember 2026-03-31 0001593184 BRGX:RelatedPartyDebtsMember 2025-12-31 0001593184 BRGX:LibertasTrustMember 2026-03-31 0001593184 BRGX:LibertasTrustMember 2025-12-31 0001593184 BRGX:WilshireHoldingTrustMember 2026-03-31 0001593184 BRGX:WilshireHoldingTrustMember 2025-12-31 0001593184 BRGX:RescoEnterprisesTrustMember 2026-03-31 0001593184 BRGX:RescoEnterprisesTrustMember 2025-12-31 0001593184 BRGX:AvisTrustMember 2026-03-31 0001593184 BRGX:AvisTrustMember 2025-12-31 0001593184 BRGX:JoesphBirdMember 2026-03-31 0001593184 BRGX:JoesphBirdMember 2025-12-31 0001593184 BRGX:ThomasPowerMember 2026-03-31 0001593184 BRGX:ThomasPowerMember 2025-12-31 0001593184 BRGX:RichardLongMember 2026-03-31 0001593184 BRGX:RichardLongMember 2025-12-31 0001593184 BRGX:JodyWalkerMember 2026-03-31 0001593184 BRGX:ResidesEnterprisesMember 2026-01-01 2026-03-31 0001593184 BRGX:ResidesEnterprisesMember 2025-01-01 2025-12-31 0001593184 BRGX:ThomasPowerMember 2026-01-01 2026-03-31 0001593184 BRGX:ThomasPowerMember 2025-01-01 2025-12-31 0001593184 BRGX:GaryHennerbergMember 2026-01-01 2026-03-31 0001593184 BRGX:GaryHennerbergMember 2025-01-01 2025-12-31 0001593184 BRGX:PriorOfficersAndBoardMembersMember 2026-03-31 0001593184 BRGX:PriorOfficersAndBoardMembersMember 2025-12-31 0001593184 BRGX:BioregenxMember BRGX:LibertasTrustMember 2026-03-31 0001593184 BRGX:BioregenxMember BRGX:WilshireHoldingTrustMember 2026-03-31 0001593184 BRGX:NuLifeSciencesMember BRGX:RescoEnterprisesTrustMember 2026-03-31 0001593184 BRGX:NuLifeSciencesMember BRGX:AvisTrustMember 2026-03-31 iso4217:USD shares iso4217:USD shares pure BRGX:Integer false --12-31 2026 Q1 0001593184 1 1 1 10-Q true 2026-03-31 false 000-56345 BIOREGENX, INC. NV 30-1912453 7407 Ziegler Road Chattanooga TN 37421 866 770-4067 Common Stock, $0.001 par value Yes Yes Non-accelerated Filer true false false 971575183 45806 69383 18383 39718 92806 106931 33297 35233 190292 251265 146778 159721 337070 410986 698974 615990 257248 355747 386754 434370 605510 567422 522500 522500 952615 1003206 1030193 1029453 56528 60227 3987822 4066415 700000 700000 182564 181825 4870386 4948240 0.001 0.001 1500000000 1500000000 971575183 971575183 969017081 969017081 971575 969017 0.001 0.001 50000000 50000000 3800 3800 3800 3800 4 4 31637084 31609289 -37141979 -37115564 -4533316 -4537254 337070 410986 426175 515147 77887 109116 348288 406031 1658 8278 30353 75633 396394 590368 398052 598646 -49764 -192615 81334 0 19101 0 38088 35455 77086 74239 23349 -74239 -26415 -266854 969173181 969173181 956994100 956994100 -0.00 -0.00 -0.00 -0.00 -26415 -266854 0 -2059 -26415 -268913 956994100 956994 3800 4 1936000 268620 30965084 -35571995 2034 -3379259 1936000 1936 -1936000 -268620 336574 69890 285715 286 5457 5743 500000 500 5400 5900 577143 577 7138 7715 -266854 -266854 -2059 -2059 960292958 960293 3800 4 0 0 31319653 -35838849 -25 -3558924 969017081 969017 3800 4 0 0 31609289 -37115564 0 -4537254 1986671 1987 21584 23571 571431 571 6211 6782 -26415 -26415 971575183 971575 3800 4 0 0 31637084 -37141979 0 -4533316 -26415 -266854 12943 12377 0 1515 6782 0 23571 75633 0 5900 3944 9789 81334 -0 -21335 -3837 -14125 29344 914 -64264 82984 71032 -98499 265 33718 61571 38088 35455 -3699 -7745 26629 37695 56017 10415 5811 0 -50206 -10415 0 -2059 -23577 25221 69383 58404 45806 83625 29688 23193 0 0 0 7715 0 7715 <p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zfHSfi6YMmzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 1—<span id="xdx_822_zgqTI8Rhe7B1">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84A_ecustom--OrganizationAndBusinessPolicyTextBlock_zzsqhrEBtHU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86F_zX2paRyxjSh">Organization and Business</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, BioRegenx, Inc., develops and manufactures medical test equipment and high quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel, to health professionals and research organizations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 the Company’s consolidated group was formed by the contribution of 100% of the equity interests of three companies, Microvascular Health Services, LLC, My Body Rx, LLC and NuLife Sciences, Inc. in exchange for newly issued common and preferred stock representing all the issued and outstanding shares of BioRegenx. The combination is expected to product synergies between companies with the production activities and the distribution network of the marketing company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, and its wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The accounting and reporting policies of the Company conform with accounting principles generally accepted in the United States of America (“US GAAP”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z88R61IC8Us1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86C_zyh10x7sqsY6">Basis of Presentation of Unaudited Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements of the Company for the three months ended March 31, 2026 and 2025 have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K for scaled disclosures for smaller reporting companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting of normal recurring adjustments,and write-offs), which are, in the opinion of the management, necessary for the fair presentation of the Company’s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for the full fiscal year. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026 (the “Annual Report”).  The balance sheet as of December 31, 2025 is derived from the Company’s audited financial statements included with that Annual Report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zeWpHqUefH57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zBCNCnLDxuze">Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates the continuation of the Company as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has generated recurring losses from operations and cash flow deficits from its operations since inception and has had to raise funds through equity offerings or borrowings to continue operating. These factors raise substantial doubt about the Company’s ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260331_zFF8dMusZ1Hg" title="Net loss">26,415</span>), generated cash from operations of $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20260101__20260331_zbNaLrDhZWU5" title="Cash in operations">26,629</span> and had a stockholder’s deficit of $<span id="xdx_906_eus-gaap--StockholdersEquity_iNI_di_c20260331_zJgzxLCDOM3" title="Stockholders' deficit">4,533,316</span> as of that date. At March 31, 2026, the Company had cash on hand in the amount of $<span id="xdx_90E_eus-gaap--Cash_iI_c20260331_zQ8SfEVYdNS8" title="Cash on hand">45,806</span>. In addition, notes payable of $<span id="xdx_907_eus-gaap--DebtDefaultShorttermDebtAmount_iI_c20260331_zeSI3R2U2NDb" title="Notes payable in default amount">522,500</span> are in default. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. Our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December 31, 2025, has also expressed substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the company cannot continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuation of the Company as a going concern is dependent upon its ability to obtain necessary debt or equity financing to continue operations until it begins generating positive cash flow. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zy8ht85kXrW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_861_zNhk4G6tTiD9">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in purchase price allocations, and assumptions made in valuing equity instruments issued for services and acquisitions. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znn8MWMP7lva" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_863_zvpJPdA3tz9k">Fair value of financial instruments</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs used to measure their fair value. Accounting Standards Codification Section 820 defines the following levels of subjectivity associated with the inputs:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1—Quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3—Unobservable inputs based on the Company’s assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of financial assets and liabilities, such as cash, accounts receivable, inventory, accounts payable, and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zvMifduAKkYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86E_zTbylBxpSEDe">Accounts Receivable</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments from the customers are typically made at the time of the order before satisfaction of the performance obligation. The Company in rare instances grants 30-day terms to select long term customers. In such instances the revenue recognition occurs when the performance obligation is satisfied. Accounts receivables are recorded at the invoiced amount and do not bear interest. The Company establishes an allowance for doubtful accounts for estimated losses inherent in its accounts receivable as determined by management. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and our customers’ financial condition, the amount of the receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts regularly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of March 31, 2026, and December 31, 2025, management determined the reserve for uncollectible accounts was adequate to provide for future losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zyGwSto4sEwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_867_zLcysWOM007a">Revenue Recognition</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company applies ASC Topic 606, <i>Revenue from Contracts with Customers</i> ("ASC 606") for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, the Company follows a five-step model as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">1 – Identification of the contract with a customer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">2 – Identification of the performance obligation in the contract</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">3 – Determination of the transaction price</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">4 – Allocation of the transaction price to the performance obligation in the contract</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">5 – Recognition of revenue when, or as, a performance obligation is satisfied</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company through its subsidiaries provides a medical testing machine, consumables for the testing process, wellness devices and nutritional supplements The company requires payment prior to shipping, with only a few exceptions. Sales are also not shipped until payment is received, typically via credit card. Shipping typically occurs in 24 hours of the payment. Sales are recorded. All product orders that are unused and returned within the first 30 days following purchase are refunded at 100% of the sales price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--RevenueRecognitionForAlternativeRevenueProgramsPolicy_zGeX73f0UFqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86B_zkAVt3yiYoGi">Other Revenue</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other sales include fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and payment fees. Such fees are amortized over the period to which they relate, typically 12 months, which is recorded as other sales income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_ecustom--RevenueRecognitionDisaggregationOfRevenuePolicyTextBlock_zkRaChhA8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_860_zoE2HS0YaL0k">Disaggregation of Revenue</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net revenue received consisted of the following product sources:</p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjE2MaBSIkQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zsvGK8DNLya1" style="display: none">Schedule of disaggregation of revenue</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">For the three months ended</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2025</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical testing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--MedicalTestingMember_zr8X0U9KRf2" style="width: 13%; text-align: right">33,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--MedicalTestingMember_zSNOMmt0ywWk" style="width: 13%; text-align: right">48,533</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wellness devices</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--WellnessDevicesMember_zVK5B7q9jqzc" style="text-align: right">9,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--WellnessDevicesMember_zRWH7bEcE0e3" style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Nutritional</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--NutritionalMember_zclnrxm9HIe5" style="text-align: right">384,570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--NutritionalMember_zTmL6JjlIroa" style="text-align: right">467,531</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other - returns</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--OtherReturnsMember_zhdmNvaNVlUl" style="border-bottom: Black 1pt solid; text-align: right">(2,007</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--OtherReturnsMember_zPb27rm7QHk4" style="border-bottom: Black 1pt solid; text-align: right">(927</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20260101__20260331_zeLWFEWCoF2h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net sales">426,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250101__20250331_zDBec7yeh4Ve" style="border-bottom: Black 2.5pt double; text-align: right" title="Net sales">515,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net revenue received consisted of the following customer types:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">For the three months ended</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical and Academic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--MedicalAndAcademicMember_zLF0K3UKQjR8" style="width: 13%; text-align: right">121,560</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--MedicalAndAcademicMember_zvnMHpre4Llc" style="width: 13%; text-align: right">167,688</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customers and Direct Sales</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--CustomersAndDirectSalesMember_zWxUAIBTmtOb" style="text-align: right">233,983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--CustomersAndDirectSalesMember_zBxStaWBu4Na" style="text-align: right">263,531</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Reseller</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--ResellerMember_zo8GifWekKbh" style="border-bottom: Black 1pt solid; text-align: right">70,632</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--ResellerMember_z9dnEAtClDWb" style="border-bottom: Black 1pt solid; text-align: right">83,928</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Net Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20260101__20260331_zERKEgZqt3af" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Net Sales">426,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20250101__20250331_zFN9VFxPqJp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Net Sales">515,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_8A8_zvCHiOLS68e2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84F_ecustom--RevenueRecognitionDeferredRevenuePolicyTextBlock_zovdGX5Cehua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_867_zs5kIXHIyno1">Deferred Revenue</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had deferred revenue of $<span id="xdx_908_eus-gaap--DeferredRevenue_iI_c20251231_zVoY9NqBC5Xj" title="Deferred revenue">60,227</span>, which was primarily related to funds received from customers in advance of shipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2026, the Company did not record revenue or refunds for its previously deferred revenue from wellness products and medical test machines. The deferred balance was reduced by $<span id="xdx_903_ecustom--EquityInstrumentsIssuedAsRefunds_pp0p0_c20260101__20260331_zkWuAIi1b9ac" title="Equity instruments issued as refunds">3,699</span> upon the reversal of unidentifiable deposit held in the deferred revenue account. As of March 31, 2026, the Company's deferred revenue had a balance of $<span id="xdx_90B_eus-gaap--DeferredRevenue_iI_c20260331_zrtVXfKCNQp3" title="Deferred revenue">56,528</span>, primarily consisting of $<span id="xdx_90D_eus-gaap--DeferredRevenue_iI_c20260331__us-gaap--DeferredRevenueArrangementTypeAxis__custom--CustomerAdvancesMember_zKvZe0b4c6v" title="Deferred revenue">33,480</span> in customer advances for products not yet shipped and $<span id="xdx_90E_eus-gaap--DeferredRevenue_iI_c20260331__us-gaap--DeferredRevenueArrangementTypeAxis__custom--DeferredShipmentsMember_zQutseyQvrd1" title="Deferred revenue">23,048</span> in deferred shipments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_ecustom--IndependentBusinessPartnersIncentivesPolicyPolicyTextBlock_zJ7WQquPlbt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86C_zcYCkFInvkx5">Independent Business Partners Incentives</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of the company’s products are distributed through a network of Independent Brand Partners (IBP). IBPs pay an annual membership fee to maintain the IBP status which is a requirement to participate in the compensation plan. IBP incentives expenses include all forms of commissions, and other incentives paid to our Independent Business Partners (IBPs). Commission expense and other amounts payable to IBPs are recorded upon recognition of sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had provided an accrual for commissions payable under this program of $<span id="xdx_90E_eus-gaap--AccruedSalesCommissionCurrent_iI_c20251231_zrGTOy3eSCZb" title="Commissions payable">166,561</span>. During the period ended March 31, 2026, the Company conducted a study of commission expense and the accumulation of the provision over the previous three years. The results of the study indicated that many of the accrued amounts were not payable, and related to old unidentified amounts that were brought forward from older systems. As such, the Company adjusted the accrual by $<span id="xdx_90D_ecustom--WriteoffOfAccruedLiabilities_c20260101__20260331_ztsMqBhqXP7c" title="Adjusted reserve">81,334</span> during the period ended March 31, 2026. As of March 31, 2026, and December 31, 2025, the Company had an accrued liability for commissions payable of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260331__us-gaap--TransactionTypeAxis__custom--CommissionsPayableMember_zh0SC7VqM68g" title="Accrued liability for warranty reserve">84,785</span> and $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CommissionsPayableMember_zycKPudGX7Y1" title="Accrued liability for warranty reserve">166,561</span>, respectively, which are included in accrued expenses in the accompanying condensed balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z4DcPUBgwtVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zH5JeDLN7nYi">Equity-Based Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically issues stock options to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, <i>Compensation-Stock Compensation</i> whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option or warrant grant is estimated using the Black-Scholes option-pricing model. The Company was a private company until March 8^th, 2024 and lacked company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zdoJwWimLe68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zwLkd7OOWeN3">Net Income (Loss) per Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><br/> We calculate basic net income (loss) per share using the weighted average number of common stock shares outstanding during the period. For the calculation of diluted net income (loss) per share, we give effect to all the shares of common stock that were outstanding during the period plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is anti-dilutive. Dilutive potential shares of common stock consist of incremental shares of common stock issuable upon exercise of stock options and warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2026 and 2025, there were no reconciling items related to either the numerator or denominator of the loss per share calculation, as their effect would have been anti-dilutive. Securities which may have affected the calculation of diluted earnings per share for the three months ended March 31, 2026 if their effect had been dilutive include <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsAndWarrantsMember_zID3goigYDq6" title="Dilutive shares">43,107,344</span> outstanding options and warrants to purchase our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7oPM2ieF6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86B_zAjZrn363fzf">Segments</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate as a <span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20260101__20260331_zaGkCjAZlPD9" title="Reportable segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0593">single</span></span> reportable segment. For consistency, depreciation of property and equipment is presented separately from amortization of intangible assets on the face of the statements, and the same convention is used in the segment information and statement of cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in one segment for the manufacture and distribution of its products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics, nature of products and services, and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZjpOsszHGPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zlgehXQlw1P6">Recently Issued Accounting Standards</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84A_ecustom--OrganizationAndBusinessPolicyTextBlock_zzsqhrEBtHU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86F_zX2paRyxjSh">Organization and Business</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, BioRegenx, Inc., develops and manufactures medical test equipment and high quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel, to health professionals and research organizations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 the Company’s consolidated group was formed by the contribution of 100% of the equity interests of three companies, Microvascular Health Services, LLC, My Body Rx, LLC and NuLife Sciences, Inc. in exchange for newly issued common and preferred stock representing all the issued and outstanding shares of BioRegenx. The combination is expected to product synergies between companies with the production activities and the distribution network of the marketing company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, and its wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The accounting and reporting policies of the Company conform with accounting principles generally accepted in the United States of America (“US GAAP”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z88R61IC8Us1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86C_zyh10x7sqsY6">Basis of Presentation of Unaudited Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements of the Company for the three months ended March 31, 2026 and 2025 have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K for scaled disclosures for smaller reporting companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting of normal recurring adjustments,and write-offs), which are, in the opinion of the management, necessary for the fair presentation of the Company’s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for the full fiscal year. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026 (the “Annual Report”).  The balance sheet as of December 31, 2025 is derived from the Company’s audited financial statements included with that Annual Report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zeWpHqUefH57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zBCNCnLDxuze">Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates the continuation of the Company as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has generated recurring losses from operations and cash flow deficits from its operations since inception and has had to raise funds through equity offerings or borrowings to continue operating. These factors raise substantial doubt about the Company’s ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260331_zFF8dMusZ1Hg" title="Net loss">26,415</span>), generated cash from operations of $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20260101__20260331_zbNaLrDhZWU5" title="Cash in operations">26,629</span> and had a stockholder’s deficit of $<span id="xdx_906_eus-gaap--StockholdersEquity_iNI_di_c20260331_zJgzxLCDOM3" title="Stockholders' deficit">4,533,316</span> as of that date. At March 31, 2026, the Company had cash on hand in the amount of $<span id="xdx_90E_eus-gaap--Cash_iI_c20260331_zQ8SfEVYdNS8" title="Cash on hand">45,806</span>. In addition, notes payable of $<span id="xdx_907_eus-gaap--DebtDefaultShorttermDebtAmount_iI_c20260331_zeSI3R2U2NDb" title="Notes payable in default amount">522,500</span> are in default. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. Our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December 31, 2025, has also expressed substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the company cannot continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuation of the Company as a going concern is dependent upon its ability to obtain necessary debt or equity financing to continue operations until it begins generating positive cash flow. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> -26415 26629 -4533316 45806 522500 <p id="xdx_84A_eus-gaap--UseOfEstimates_zy8ht85kXrW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_861_zNhk4G6tTiD9">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in purchase price allocations, and assumptions made in valuing equity instruments issued for services and acquisitions. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znn8MWMP7lva" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_863_zvpJPdA3tz9k">Fair value of financial instruments</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs used to measure their fair value. Accounting Standards Codification Section 820 defines the following levels of subjectivity associated with the inputs:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1—Quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3—Unobservable inputs based on the Company’s assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of financial assets and liabilities, such as cash, accounts receivable, inventory, accounts payable, and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zvMifduAKkYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86E_zTbylBxpSEDe">Accounts Receivable</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments from the customers are typically made at the time of the order before satisfaction of the performance obligation. The Company in rare instances grants 30-day terms to select long term customers. In such instances the revenue recognition occurs when the performance obligation is satisfied. Accounts receivables are recorded at the invoiced amount and do not bear interest. The Company establishes an allowance for doubtful accounts for estimated losses inherent in its accounts receivable as determined by management. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and our customers’ financial condition, the amount of the receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts regularly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of March 31, 2026, and December 31, 2025, management determined the reserve for uncollectible accounts was adequate to provide for future losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zyGwSto4sEwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_867_zLcysWOM007a">Revenue Recognition</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company applies ASC Topic 606, <i>Revenue from Contracts with Customers</i> ("ASC 606") for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, the Company follows a five-step model as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">1 – Identification of the contract with a customer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">2 – Identification of the performance obligation in the contract</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">3 – Determination of the transaction price</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">4 – Allocation of the transaction price to the performance obligation in the contract</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">5 – Recognition of revenue when, or as, a performance obligation is satisfied</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company through its subsidiaries provides a medical testing machine, consumables for the testing process, wellness devices and nutritional supplements The company requires payment prior to shipping, with only a few exceptions. Sales are also not shipped until payment is received, typically via credit card. Shipping typically occurs in 24 hours of the payment. Sales are recorded. All product orders that are unused and returned within the first 30 days following purchase are refunded at 100% of the sales price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--RevenueRecognitionForAlternativeRevenueProgramsPolicy_zGeX73f0UFqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86B_zkAVt3yiYoGi">Other Revenue</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other sales include fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and payment fees. Such fees are amortized over the period to which they relate, typically 12 months, which is recorded as other sales income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_ecustom--RevenueRecognitionDisaggregationOfRevenuePolicyTextBlock_zkRaChhA8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_860_zoE2HS0YaL0k">Disaggregation of Revenue</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net revenue received consisted of the following product sources:</p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjE2MaBSIkQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zsvGK8DNLya1" style="display: none">Schedule of disaggregation of revenue</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">For the three months ended</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2025</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical testing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--MedicalTestingMember_zr8X0U9KRf2" style="width: 13%; text-align: right">33,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--MedicalTestingMember_zSNOMmt0ywWk" style="width: 13%; text-align: right">48,533</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wellness devices</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--WellnessDevicesMember_zVK5B7q9jqzc" style="text-align: right">9,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--WellnessDevicesMember_zRWH7bEcE0e3" style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Nutritional</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--NutritionalMember_zclnrxm9HIe5" style="text-align: right">384,570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--NutritionalMember_zTmL6JjlIroa" style="text-align: right">467,531</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other - returns</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--OtherReturnsMember_zhdmNvaNVlUl" style="border-bottom: Black 1pt solid; text-align: right">(2,007</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--OtherReturnsMember_zPb27rm7QHk4" style="border-bottom: Black 1pt solid; text-align: right">(927</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20260101__20260331_zeLWFEWCoF2h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net sales">426,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250101__20250331_zDBec7yeh4Ve" style="border-bottom: Black 2.5pt double; text-align: right" title="Net sales">515,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net revenue received consisted of the following customer types:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">For the three months ended</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical and Academic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--MedicalAndAcademicMember_zLF0K3UKQjR8" style="width: 13%; text-align: right">121,560</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--MedicalAndAcademicMember_zvnMHpre4Llc" style="width: 13%; text-align: right">167,688</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customers and Direct Sales</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--CustomersAndDirectSalesMember_zWxUAIBTmtOb" style="text-align: right">233,983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--CustomersAndDirectSalesMember_zBxStaWBu4Na" style="text-align: right">263,531</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Reseller</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--ResellerMember_zo8GifWekKbh" style="border-bottom: Black 1pt solid; text-align: right">70,632</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--ResellerMember_z9dnEAtClDWb" style="border-bottom: Black 1pt solid; text-align: right">83,928</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Net Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20260101__20260331_zERKEgZqt3af" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Net Sales">426,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20250101__20250331_zFN9VFxPqJp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Net Sales">515,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_8A8_zvCHiOLS68e2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjE2MaBSIkQ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zsvGK8DNLya1" style="display: none">Schedule of disaggregation of revenue</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">For the three months ended</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2025</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical testing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--MedicalTestingMember_zr8X0U9KRf2" style="width: 13%; text-align: right">33,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--MedicalTestingMember_zSNOMmt0ywWk" style="width: 13%; text-align: right">48,533</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wellness devices</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--WellnessDevicesMember_zVK5B7q9jqzc" style="text-align: right">9,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--WellnessDevicesMember_zRWH7bEcE0e3" style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Nutritional</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--NutritionalMember_zclnrxm9HIe5" style="text-align: right">384,570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--NutritionalMember_zTmL6JjlIroa" style="text-align: right">467,531</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other - returns</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--ProductOrServiceAxis__custom--OtherReturnsMember_zhdmNvaNVlUl" style="border-bottom: Black 1pt solid; text-align: right">(2,007</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--ProductOrServiceAxis__custom--OtherReturnsMember_zPb27rm7QHk4" style="border-bottom: Black 1pt solid; text-align: right">(927</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20260101__20260331_zeLWFEWCoF2h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net sales">426,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250101__20250331_zDBec7yeh4Ve" style="border-bottom: Black 2.5pt double; text-align: right" title="Net sales">515,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net revenue received consisted of the following customer types:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">For the three months ended</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical and Academic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--MedicalAndAcademicMember_zLF0K3UKQjR8" style="width: 13%; text-align: right">121,560</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--MedicalAndAcademicMember_zvnMHpre4Llc" style="width: 13%; text-align: right">167,688</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customers and Direct Sales</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--CustomersAndDirectSalesMember_zWxUAIBTmtOb" style="text-align: right">233,983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--CustomersAndDirectSalesMember_zBxStaWBu4Na" style="text-align: right">263,531</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Reseller</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20260101__20260331__srt--MajorCustomersAxis__custom--ResellerMember_zo8GifWekKbh" style="border-bottom: Black 1pt solid; text-align: right">70,632</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250101__20250331__srt--MajorCustomersAxis__custom--ResellerMember_z9dnEAtClDWb" style="border-bottom: Black 1pt solid; text-align: right">83,928</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Net Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20260101__20260331_zERKEgZqt3af" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Net Sales">426,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_pp0p0_c20250101__20250331_zFN9VFxPqJp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Net Sales">515,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> 33816 48533 9796 10 384570 467531 -2007 -927 426175 515147 121560 167688 233983 263531 70632 83928 426175 515147 <p id="xdx_84F_ecustom--RevenueRecognitionDeferredRevenuePolicyTextBlock_zovdGX5Cehua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_867_zs5kIXHIyno1">Deferred Revenue</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had deferred revenue of $<span id="xdx_908_eus-gaap--DeferredRevenue_iI_c20251231_zVoY9NqBC5Xj" title="Deferred revenue">60,227</span>, which was primarily related to funds received from customers in advance of shipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2026, the Company did not record revenue or refunds for its previously deferred revenue from wellness products and medical test machines. The deferred balance was reduced by $<span id="xdx_903_ecustom--EquityInstrumentsIssuedAsRefunds_pp0p0_c20260101__20260331_zkWuAIi1b9ac" title="Equity instruments issued as refunds">3,699</span> upon the reversal of unidentifiable deposit held in the deferred revenue account. As of March 31, 2026, the Company's deferred revenue had a balance of $<span id="xdx_90B_eus-gaap--DeferredRevenue_iI_c20260331_zrtVXfKCNQp3" title="Deferred revenue">56,528</span>, primarily consisting of $<span id="xdx_90D_eus-gaap--DeferredRevenue_iI_c20260331__us-gaap--DeferredRevenueArrangementTypeAxis__custom--CustomerAdvancesMember_zKvZe0b4c6v" title="Deferred revenue">33,480</span> in customer advances for products not yet shipped and $<span id="xdx_90E_eus-gaap--DeferredRevenue_iI_c20260331__us-gaap--DeferredRevenueArrangementTypeAxis__custom--DeferredShipmentsMember_zQutseyQvrd1" title="Deferred revenue">23,048</span> in deferred shipments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 60227 3699 56528 33480 23048 <p id="xdx_84A_ecustom--IndependentBusinessPartnersIncentivesPolicyPolicyTextBlock_zJ7WQquPlbt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_86C_zcYCkFInvkx5">Independent Business Partners Incentives</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of the company’s products are distributed through a network of Independent Brand Partners (IBP). IBPs pay an annual membership fee to maintain the IBP status which is a requirement to participate in the compensation plan. IBP incentives expenses include all forms of commissions, and other incentives paid to our Independent Business Partners (IBPs). Commission expense and other amounts payable to IBPs are recorded upon recognition of sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had provided an accrual for commissions payable under this program of $<span id="xdx_90E_eus-gaap--AccruedSalesCommissionCurrent_iI_c20251231_zrGTOy3eSCZb" title="Commissions payable">166,561</span>. During the period ended March 31, 2026, the Company conducted a study of commission expense and the accumulation of the provision over the previous three years. The results of the study indicated that many of the accrued amounts were not payable, and related to old unidentified amounts that were brought forward from older systems. As such, the Company adjusted the accrual by $<span id="xdx_90D_ecustom--WriteoffOfAccruedLiabilities_c20260101__20260331_ztsMqBhqXP7c" title="Adjusted reserve">81,334</span> during the period ended March 31, 2026. As of March 31, 2026, and December 31, 2025, the Company had an accrued liability for commissions payable of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260331__us-gaap--TransactionTypeAxis__custom--CommissionsPayableMember_zh0SC7VqM68g" title="Accrued liability for warranty reserve">84,785</span> and $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_iI_c20251231__us-gaap--TransactionTypeAxis__custom--CommissionsPayableMember_zycKPudGX7Y1" title="Accrued liability for warranty reserve">166,561</span>, respectively, which are included in accrued expenses in the accompanying condensed balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 166561 81334 84785 166561 <p id="xdx_847_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z4DcPUBgwtVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zH5JeDLN7nYi">Equity-Based Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically issues stock options to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, <i>Compensation-Stock Compensation</i> whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option or warrant grant is estimated using the Black-Scholes option-pricing model. The Company was a private company until March 8^th, 2024 and lacked company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zdoJwWimLe68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zwLkd7OOWeN3">Net Income (Loss) per Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><br/> We calculate basic net income (loss) per share using the weighted average number of common stock shares outstanding during the period. For the calculation of diluted net income (loss) per share, we give effect to all the shares of common stock that were outstanding during the period plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is anti-dilutive. Dilutive potential shares of common stock consist of incremental shares of common stock issuable upon exercise of stock options and warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2026 and 2025, there were no reconciling items related to either the numerator or denominator of the loss per share calculation, as their effect would have been anti-dilutive. Securities which may have affected the calculation of diluted earnings per share for the three months ended March 31, 2026 if their effect had been dilutive include <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsAndWarrantsMember_zID3goigYDq6" title="Dilutive shares">43,107,344</span> outstanding options and warrants to purchase our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 43107344 <p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7oPM2ieF6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86B_zAjZrn363fzf">Segments</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate as a <span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20260101__20260331_zaGkCjAZlPD9" title="Reportable segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0593">single</span></span> reportable segment. For consistency, depreciation of property and equipment is presented separately from amortization of intangible assets on the face of the statements, and the same convention is used in the segment information and statement of cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in one segment for the manufacture and distribution of its products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics, nature of products and services, and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZjpOsszHGPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zlgehXQlw1P6">Recently Issued Accounting Standards</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_ziFVLikypRD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 2—<span id="xdx_82F_ztOz5rYJxEOg">INVENTORIES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories, which consist of finished goods, are comprised of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zQWIrRILdpVk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_z849CoNrjaN7" style="display: none">Schedule of inventories</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20260331_z7G0VtPb53B9" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20251231_zpxZ5vjYkAw3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Finished Goods:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_hsrt--ProductOrServiceAxis__custom--MedicalTestingMember_z7gdQhzE8IGc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical testing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,321</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,849</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_hsrt--ProductOrServiceAxis__custom--WellnessDevicesMember_zbQ8V11k1vs7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wellness devices</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_hsrt--ProductOrServiceAxis__custom--NutritionalMember_zwiegYGn7Gaa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Nutritional</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">66,848</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,087</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_zY7575WlPurh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Finished Goods</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">92,806</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">106,931</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical testing equipment components were purchased and assembled once orders were received during the financial statement period. The medical testing components are salable separately in the form received. Nutritional inventories are purchased in finished form with labels purchased separately in an amount to support the production run.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zQWIrRILdpVk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_z849CoNrjaN7" style="display: none">Schedule of inventories</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20260331_z7G0VtPb53B9" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20251231_zpxZ5vjYkAw3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Finished Goods:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_hsrt--ProductOrServiceAxis__custom--MedicalTestingMember_z7gdQhzE8IGc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Medical testing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,321</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,849</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_hsrt--ProductOrServiceAxis__custom--WellnessDevicesMember_zbQ8V11k1vs7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wellness devices</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_hsrt--ProductOrServiceAxis__custom--NutritionalMember_zwiegYGn7Gaa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Nutritional</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">66,848</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,087</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_zY7575WlPurh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Finished Goods</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">92,806</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">106,931</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2321 4849 23637 74995 66848 27087 92806 106931 <p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_zz95RSlLvtbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 3—<span id="xdx_82D_zXMGk0Y86j2i">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid expenses and other current assets consisted of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zsQpQw1KBB8c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B4_zpzZ0FIUjNF8" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20260331_zcfNulPRVEQa" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20251231_zVhgSYAHCgul" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="padding-bottom: 1pt"><b> </b></td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_pp0p0_maPEAOAzQpR_ztBs9YPFisZ3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Prepaid commissions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">5,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">5,163</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPEAOAzQpR_zh4jpeTOKCqj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,134</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,070</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzQpR_zcdAor7MMkba" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,233</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zsQpQw1KBB8c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B4_zpzZ0FIUjNF8" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20260331_zcfNulPRVEQa" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20251231_zVhgSYAHCgul" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="padding-bottom: 1pt"><b> </b></td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_pp0p0_maPEAOAzQpR_ztBs9YPFisZ3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Prepaid commissions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">5,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">5,163</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPEAOAzQpR_zh4jpeTOKCqj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,134</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,070</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzQpR_zcdAor7MMkba" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,233</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5163 5163 28134 30070 33297 35233 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0yhnRjsPj6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 4—<span id="xdx_821_zRn4I6AEfLpi">ISSUANCE OF COMMON STOCK AND OPTIONS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Issuance of common stock for services</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended March 31, 2024 the Company granted <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--TwoConsultantsMember_zN4iBtVhk1Ih" title="Stock issued for services">7,912,000</span> shares of its common stock with a fair value of $<span id="xdx_902_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--TwoConsultantsMember_zmHY15dvDB74" title="Stock granted for services, value">1,097,790</span> to two consultants for services. One tranche of shares of stock issued had a vesting term of 50% at grant date, 25% on 1^st year anniversary date, and the remaining 25% on 2^nd year anniversary from grant date. During the period ended December 31, 2025 shares with a fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--TwoConsultantsMember_zXQqKbODXL08" title="Share based compensation">202,899</span> vested and are included in selling, general and administrative expenses. In February, 2025, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20250201__20250228__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--TwoConsultantsMember_zeTyISIsgDE3" title="Share based compensation">1,936,000</span> shares issuable at December 31, 2024 were issued and the fair value of those shares of $268,620 was released to additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three months ended March 31, 2026, equity compensation was recorded for contractors and a professional who were granted a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--ContractorsAndProfessionalMember_zjAPvInSG6cf" title="Stock issued for services, shares">1,986,671</span> common shares with an aggregate value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--ContractorsAndProfessionalMember_zK3r99Vyu9r9" title="Stock issued for services, value">23,571</span>. The shares were fully vested when issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><i>Issuance of common stock to Directors and other related parties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three month period ended March 31, 2025 the Company granted <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--DirectorsAndAnOfficerMember_zbJsctYgZmqk" title="Stock issued for services, shares">285,715</span> shares of its common stock with an aggregate fair value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--DirectorsAndAnOfficerMember_z5ccucuNG5b9" title="Stock issued for services, value">5,743</span> to its directors and officers for services provided. The shares were fully vested when issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three months ended March 31, 2026, equity compensation was recorded for board members and officers who were granted a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--BoardMembersAndOfficersMember_zQ0mH1oorPCd" title="Stock issued for services, shares">571,431</span> common shares with an aggregate value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--BoardMembersAndOfficersMember_zBGhsZFcFpKa" title="Stock issued for services, value">6,782</span>. The shares were fully vested when issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Issuance of common stock as loan incentives</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2025, the Company granted <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--TwoNoteHoldersMember_z6J5qvmzycq3" title="Stock issued new, shares">500,000</span> shares of its common stock with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueOther_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--TwoNoteHoldersMember_zC8eINcDTuHl" title="Stock issued new, value">5,900</span> to two note holders as a loan fee and other advances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts owed to a director were converted to <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231_zhURMHC0bt69" title="Stock converted, shares converted">97,370</span> common shares with a fair value of $<span id="xdx_905_eus-gaap--ConversionOfStockAmountConverted1_c20250101__20251231_zdLRuiOWbEF8" title="Shares converted, value">974</span> during the year ended December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares issued for grants before the end of the three months ended March 31, 2026, and issued before the filing of these financial statements are treated as outstanding share in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of all stock options and warrants outstanding as of March 31, 2026, without the effect of forfeitures, follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ze7Px6iTsHL1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ISSUANCE OF COMMON STOCK AND OPTIONS (Details - Stock options and warrants outstanding)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zqwVAhAn2x9i" style="display: none">Schedule of stock options and warrants outstanding</span></td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of <br/> Shares</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise Price</b></p></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2025</span></td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zpI2vhaidON5" style="width: 13%; text-align: right" title="Number of shares, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zWJMVWqYfPk6" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zCF2RM9NqSRi" style="text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zlfrnaVh4Gxh" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zkQAcxItV2Ni" style="text-align: right" title="Number of shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zcUeAw9U6nuf" style="text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zE3FUtUqmbre" style="border-bottom: black 1pt solid; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zWLgZwjFYAy8" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of March 31, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zdg2ZrjHN7Ee" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zAmUeAKe2Pt6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at March 31, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_z6fb9dEGe0We" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zxy6s9rbl4H6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td> <td> </td></tr> </table> <p id="xdx_8AF_zdxrsJXJJNnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options and Warrants Outstanding and Exercisable at March 31, 2026:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zedq3iLga0Ca" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ISSUANCE OF COMMON STOCK AND OPTIONS (Details - Warrants outstanding and exercisable)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B2_z55Pr9Ac7qh" style="display: none">Schedule of options and warrants outstanding and exercisable</span></td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of <br/> Exercise Price</b></span></td> <td style="width: 4%"> </td> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>#of Options and Warrants Exercisable</b></span></td> <td style="width: 4%"> </td> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average <br/> Exercise Price</b></span></td> <td style="width: 4%"> </td> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining (Years)</b></span></td></tr> <tr style="background-color: rgb(238,238,238)"> <td style="border-top: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEVFNWyl8SA5" title="Range of exercise price, lower range">0.09</span> to <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvkP6fQAPwU1" title="Range of exercise price, upper range">0.20</span></span></td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUZynznpA8Wi" style="border-top: black 1pt solid; text-align: center" title="Options and warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td> </td> <td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXORkCp5VsB6" style="border-top: black 1pt solid; text-align: center" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.16</span></td> <td> </td> <td style="border-top: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zp5rdRjx4Ekf" title="Weighted average remaining (years)">4.94</span></span></td></tr> </table> <p id="xdx_8A5_zuxTeTP2qy6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outstanding and exercisable options and warrants had <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_do_c20260331_zx5q2OBTK0Bj" title="Warrants outstanding"><span id="xdx_90F_ecustom--WarrantsExercisable_iI_do_c20260331_z9VChW3JDhu3" title="Warrants exercisable">no</span></span> intrinsic as on March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 7912000 1097790 202899 1936000 1986671 23571 285715 5743 571431 6782 500000 5900 97370 974 <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ze7Px6iTsHL1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ISSUANCE OF COMMON STOCK AND OPTIONS (Details - Stock options and warrants outstanding)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zqwVAhAn2x9i" style="display: none">Schedule of stock options and warrants outstanding</span></td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of <br/> Shares</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise Price</b></p></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2025</span></td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zpI2vhaidON5" style="width: 13%; text-align: right" title="Number of shares, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zWJMVWqYfPk6" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zCF2RM9NqSRi" style="text-align: right" title="Number of shares, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zlfrnaVh4Gxh" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zkQAcxItV2Ni" style="text-align: right" title="Number of shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zcUeAw9U6nuf" style="text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zE3FUtUqmbre" style="border-bottom: black 1pt solid; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zWLgZwjFYAy8" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of March 31, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zdg2ZrjHN7Ee" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zAmUeAKe2Pt6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at March 31, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_z6fb9dEGe0We" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--StockOptionAndWarrantsMember_zxy6s9rbl4H6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16</span></td> <td> </td></tr> </table> 43107344 0.16 -0 -0 0 0 0 0 43107344 0.16 43107344 0.16 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zedq3iLga0Ca" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ISSUANCE OF COMMON STOCK AND OPTIONS (Details - Warrants outstanding and exercisable)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B2_z55Pr9Ac7qh" style="display: none">Schedule of options and warrants outstanding and exercisable</span></td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of <br/> Exercise Price</b></span></td> <td style="width: 4%"> </td> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>#of Options and Warrants Exercisable</b></span></td> <td style="width: 4%"> </td> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average <br/> Exercise Price</b></span></td> <td style="width: 4%"> </td> <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining (Years)</b></span></td></tr> <tr style="background-color: rgb(238,238,238)"> <td style="border-top: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEVFNWyl8SA5" title="Range of exercise price, lower range">0.09</span> to <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvkP6fQAPwU1" title="Range of exercise price, upper range">0.20</span></span></td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUZynznpA8Wi" style="border-top: black 1pt solid; text-align: center" title="Options and warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,107,344</span></td> <td> </td> <td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXORkCp5VsB6" style="border-top: black 1pt solid; text-align: center" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.16</span></td> <td> </td> <td style="border-top: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zp5rdRjx4Ekf" title="Weighted average remaining (years)">4.94</span></span></td></tr> </table> 0.09 0.20 43107344 0.16 P4Y11M8D 0 0 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zZqo388fFGR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 5—<span id="xdx_825_z0EjYKJNOCP8">LOANS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through certain subsidiaries, financed past activities, in part, with borrowing from private parties, Small Business Administration’s Economic Injury Disaster Loans (EIDL) and related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loans from unrelated parties are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zaQ8IJsF66Z4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOANS (Details - Loans from unrelated parties)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zaUZgj1iTKs5" style="display: none">Schedule of loans from unrelated parties</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">(A) Howard notes - In Default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--HowardNotesMember_zIbJIL2Jshy5" style="width: 13%; text-align: right" title="Loans from unrelated parties">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--HowardNotesMember_pp0p0" style="width: 13%; text-align: right" title="Loans from unrelated parties">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(B) Goff note - In Default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--GoffNoteMember_zeemO7Il7HDd" style="text-align: right" title="Loans from unrelated parties">22,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--GoffNoteMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">22,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">(C) Insurance notes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--InsuranceNotesMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">4,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceNotesMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">6,083</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(D) Alder note, net of discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--AlderNotesNetOfDiscountMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">263,767</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--AlderNotesNetOfDiscountMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">285,864</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">(E) EIDL notes ($400,000 in default)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LoansPayable_iI_pp0p0_c20260331__us-gaap--LongtermDebtTypeAxis__custom--EIDLNotesMember_zIxJl5xYy5Ab" style="text-align: right" title="Loans from unrelated parties">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--EIDLNotesMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">550,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(F) Stripe Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">22,729</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">52,280</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">(G) Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--OtherNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Loans from unrelated parties">171,510</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--OtherNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Loans from unrelated parties">168,304</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LoansPayable_c20260331_pp0p0" style="text-align: right" title="Loans from unrelated parties">1,135,179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LoansPayable_c20251231_pp0p0" style="text-align: right" title="Loans from unrelated parties">1,185,031</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LoansPayableCurrent_iNI_pp0p0_di_c20260331_zMtFi3l1qN9h" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(952,615</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LoansPayableCurrent_iNI_pp0p0_di_c20251231_zOHZEgVHrAd2" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(1,003,206</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total long term</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LongTermLoansPayable_c20260331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total long term">182,564</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LongTermLoansPayable_c20251231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total long term">181,825</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zzOC47SS5JJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(A) The Company has two outstanding unsecured Howard Notes that are both in default. The first Howard note was advanced on June 28^th, 2016 and the second on April 3^rd, 2017 to Microvascular Health Solutions, LLC. Both notes are for $<span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--HowardNoteMember_zGnmStC9jraj" title="Notes in default">50,000</span> and had one-year terms, both notes are in default. The stated interest rate on each note was 2.5% per month, upon default the interest rate increased to 3.5% per month. The notes are secured by the accounts receivable of the borrower. At year end after the default each note contained a provision entitling the lender to 5% ownership in the borrower, a consolidated subsidiary. The Company estimates that if the interest in the subsidiary were converted into its common shares it would represent an equivalent of 29,400,000 shares, which would only be issuable at the option of the Company in lieu of the interest in the subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(B) The Goff note had a maturity date of February 13^th, 2016, the note is in default. The original note advanced $15,000 and called for a payment of $22,500 on the maturity date. The note provides for a 4% interest rate per annum after the maturity date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(C) Insurance notes are from finance companies that provided short term financing of insurance premiums. The notes require ten installments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">((D) In January 10^th, 2024, the Company issued two unsecured notes for $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240110__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember__srt--CounterpartyNameAxis__custom--DocSunBiomedicalHoldingsIncMember_zWhfwbhDgqR7" title="Unsecured notes">165,000</span> each to Adler and Genesis Glass. The notes are due in twelve months from the note date or before if the company brings in equity equal to $1,500,000. The funds were designated for the improvement of the technical infrastructure of the newly acquired DocSun Biomedical Holdings, Inc. Each note was issued with a $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20240109__20240110__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember__srt--CounterpartyNameAxis__custom--DocSunBiomedicalHoldingsIncMember_zuzFNh0UB9u5" title="Note issued">15,000</span> original issue discount and the issuance of <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240109__20240110__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember__srt--CounterpartyNameAxis__custom--DocSunBiomedicalHoldingsIncMember_zcPpRIODRLUh" title="Shares issued">72,000</span> common shares with a fair value of $<span id="xdx_904_eus-gaap--LongTermDebtFairValue_iI_c20240110__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember__srt--CounterpartyNameAxis__custom--DocSunBiomedicalHoldingsIncMember_zFEg22obIrbe" title="Fair value">9,990</span> were paid to each lender as an additional loan fee, resulting in an aggregate loan discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240110__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember__srt--CounterpartyNameAxis__custom--DocSunBiomedicalHoldingsIncMember_zmM9Xgv4v7bg" title="Loan discount">49,980</span> which was fully amortized over the initial life of the loan. Subsequent to year end the loans were extended until October 9^th, 2025 by agreement with the lender. The extension terms call for 1% interest per month and $5,000 payments per month on the Adler note until May 2025 at which time the payments become $5,000 per month for each note. The Company issued 250,000 common shares to the lender for each note extended. As of December 31, 2024, the aggregate principal and interest due under the notes was $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231_ztUXxPvd8Sm6" title="Aggregate principal">328,644</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9^th, 2025, the Adler and Genesis Glass notes were combined into a single note payable to Adler with a principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_zq7KfLP8C9Mf" title="Principal balance">295,207</span> and the term was extended to October 10, 2026. In the event that the Company raises over $<span id="xdx_900_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_c20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_zn101oQFd3T8" title="Equity or debt financing">2,000,000</span> in equity or debt financing <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20251008__20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_z6X9ZEvmm5sj" title="Financing interest rate">10</span>% of the amount raised will be applied to the note until the principal is paid off. The extension terms call for 1% interest per month and $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20251008__20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_z6oPWJSNOnDh" title="Payments of principal and interest per month">10,000</span> payments of principal and interest per month. In the event of an uplist of the Company to a national exchange, the lender has the option to convert the outstanding principal balance of the note into the Company’s common shares for 90 days after the uplist. The conversions price is fixed at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_zVTNNujmnph4" title="Conversions price">0.1325</span> per share. In the event of default, the Company will issue the lender <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251008__20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_zTlRxVo17Tv5" title="Number of shares issued">3,000,000</span> shares of its common stock and the monthly interest rate increases to <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251009__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_zowwJMprqXta" title="Debt stated interest rate">1.5</span>% and the lender has the right to require immediate payment in full. The company made principal payments of $<span id="xdx_902_eus-gaap--PaymentsForLoans_c20260101__20260331__us-gaap--LongtermDebtTypeAxis__custom--GenisisGlassNoteMember_zoV7gyvDtoJ4" title="Principal payments">22,097</span> during the period ended March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(E) Long Term Notes – EIDL</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As principal amount of economic injury disaster loans (EIDL) issued under the Small Business Administration’s COVID-19 recovery program was $<span id="xdx_904_eus-gaap--LongTermDebt_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--EIDLLoanMember__us-gaap--LongtermDebtTypeAxis__custom--SBALoan1Member_zmsP0kbT4yyd" title="Debt outstanding">550,000</span> and $<span id="xdx_902_eus-gaap--LongTermDebt_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--EIDLLoanMember__us-gaap--LongtermDebtTypeAxis__custom--SBALoan2Member_zgYP3bHYBs5j" title="Debt outstanding">550,000</span> at March 31, 2026 and December 31, 2025, respectively. At December 31, 2025, the long-term balance of the EIDL loans was $<span id="xdx_908_eus-gaap--LongTermDebtCurrent_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--EIDLLoanMember_z7xT0bosluLj" title="Long-term balance">150,000</span> and the current balance for delinquent loans was $<span id="xdx_901_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--EIDLLoanMember_zAKw6PylVBv4" title="Defaulted loan">400,000</span>. The total balance is comprised of three notes made by subsidiaries of the Company, secured by the assets of the Company. One of which was acquired in the merger with Findit, Inc. and is in charge off status at the SBA. The Findit EIDL loan and the other $<span id="xdx_904_eus-gaap--OtherLiabilitiesCurrent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--EIDLLoanMember_zUcoGUwJsOb3" title="Current liabilities">200,000</span> subsidiary loan are in default and shown as current liabilities. Each loan has a 30-year term and an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260331__us-gaap--DebtInstrumentAxis__custom--EIDLLoanMember_zWTJMzpf0ed6" title="Debt stated interest rate">3.75</span>% per annum. The SBA granted a total of thirty months payment deferment period under the EIDL program for Covid-19 related loans, both EIDL loans qualified for and used the full deferment period. Interest continued to accrue during the deferment period and the deferred amounts will be paid as a balloon payment at the end of the 30-year amortization period. Current payments are being applied against interest accrued. The notes maturity dates are May 17, 2050 for a $150,000 note, July 12, 2051 for a $200,000 note and July 17, 2050 for the $200,000 Findit EIDL loan. As of March 31, 2026, the Company was delinquent on payments on two of the EIDL loans in the aggregate amount of $400,000, and such amounts have been reflected as current in the accompanying financial statements. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(F) On July 24th 2025, the Company took out a loan from Stripe Capital, a company affiliated with one of its credit card processors. The original principal of the loan was $<span id="xdx_907_eus-gaap--ProceedsFromLoans_c20250723__20250724__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_z5ORBxWNg5zf" title="Proceeds from loan">105,800</span>. The finance charge is stated as a fixed amount of $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20250723__20250724__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_zL20fIm8tM88" title="Interest expense">7,935</span> or <span id="xdx_904_eus-gaap--LoansReceivableBasisSpreadOnVariableRateDuringPeriod_dp_c20250723__20250724__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_zkUtU3wcGI8h" title="Loan rate">7</span>% of the amount to be repaid. Payments are made on a daily basis with 22% of the sales volume processed through the Stripe merchant account being applied against the total amount to be repaid. There is a minimum repayment amount of $12,637 that applies to each 60-day period which has not affected the repayment amounts as of December 31, 2025. The loan does not have a fixed term for repayment but is expected to be fully repaid in 8 to 10 months. The company made principal payments of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_zkXyqvxwdMC" title="Principal payments">29,550</span> during the period ended March 31, 2026. The remaining principal balance at March 31, 2026 is $<span id="xdx_901_eus-gaap--LoansPayable_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_zgeNu2CuSPV4" title="Loans payable">22,729</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(G) As of March 31, 2026, five notes were issued for proceeds totaling $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--OtherNotesMember_zJiSH8auopD3" title="Debt face amount">160,000</span>. One of the convertible notes with an original principal amount of $30,000 is owned to a related party and the balance is reported in the Related Party Loans section below. The convertible notes have a stated interest rate of 16%, of which 10% is payable by adding to the principal of the note and 6% is payable in cash, biannually. The notes are convertible into common shares at the option of the noteholder at 0.09 cents per common share. The notes mature 2 years after the note date. The Company has the option to convert the convertible notes in the event of an uplift to a national stock exchange. The conversion price to the Company is the lesser of 0.09 cents or 85% of the price at on the national exchange. For each $5,000 principal of the notes, the Company granted 2,500 warrants to purchase common stock at 0.20 cents per common share. The warrants expire 2 years after the Company’s shares are listed on an internationally recognized exchange. The balance of the principal and accrued interest was $<span id="xdx_906_eus-gaap--NotesAndLoansPayable_iI_c20260331_zYaqnoV0Awwa" title="Balance principal">171,510</span> and $<span id="xdx_900_eus-gaap--NotesAndLoansPayable_iI_c20251231_zyuHDJAH83ua" title="Balance principal">168,304</span> at March 31, 2026 and December 31, 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, payments on two of the Economic Injury Disaster Loan (EIDL) facilities were delinquent. Consistent with the Company’s policy, any past-due principal and interest amounts payable within twelve months are classified as current liabilities on the condensed consolidated balance sheet. Management is pursuing extensions and other arrangements to cure delinquencies and improve liquidity. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Related Party Loans</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioRegenx and its subsidiaries have financed past activities, in part, with unsecured borrowings from certain related parties. Each of the listed loans below indicated with an A are demand loans that have a one-year term and an auto renewal feature. They bear interest rates from 8% to 16% per annum. The loan indicated with a B does not have stated terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal amount of debt from related parties is summarized in the following table:</p> <table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfRelatdPartyDebtTableTextBlock_zTSsxVndJVH7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOANS (Details - Related party debt)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8BA_zMYEKaPk3O26" style="display: none">Schedule of related party debt</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Related Party</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 61%; text-align: left">Libertas Trust</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertasTrustMember_fKEEp_z6McZJqPhRla" style="width: 13%; text-align: right" title="Note payable - related party">180,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertasTrustMember_fKEEp_zHWORrZdrMUk" style="width: 13%; text-align: right" title="Note payable - related party">180,000</td><td style="width: 1%; text-align: left"> </td> <td style="width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wilshire Holding Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilshireHoldingTrustMember_fKEEp_zjXhnHLQyH38" style="text-align: right" title="Note payable - related party">518,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilshireHoldingTrustMember_fKEEp_zxZNxgyduVle" style="text-align: right" title="Note payable - related party">518,000</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Resco Enterprises Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RescoEnterprisesTrustMember_fKEEp_zEn1JoTJ9Aji" style="text-align: right" title="Note payable - related party">157,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RescoEnterprisesTrustMember_fKEEp_znH4nESW2Ygk" style="text-align: right" title="Note payable - related party">157,747</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Avis Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvisTrustMember_fKEEp_zznJ1Yxvv9Fb" style="text-align: right" title="Note payable - related party">67,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvisTrustMember_fKEEp_zWy1tOEwtLme" style="text-align: right" title="Note payable - related party">67,606</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">JS Bird</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JoesphBirdMember_fKEEp_z0leeczmL34b" style="text-align: right" title="Note payable - related party">32,079</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JoesphBirdMember_fKEEp_zDb4DtK86XEi" style="text-align: right" title="Note payable - related party">32,079</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thomas Power</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThomasPowerMember_fKEEp_zPWCcay0rjCi" style="text-align: right" title="Note payable - related party">34,899</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThomasPowerMember_fKEEp_z9cONgCldcG3" style="text-align: right" title="Note payable - related party">34,159</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Richard Long</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RichardLongMember_fKEIp_zanDyAWwJB5b" style="border-bottom: Black 1pt solid; text-align: right" title="Note payable - related party">39,862</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RichardLongMember_fKEIp_zsH5gKbkoUrl" style="border-bottom: Black 1pt solid; text-align: right" title="Note payable - related party">39,862</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_c20260331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable - related party">1,030,193</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_c20251231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable - related party">1,029,453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"><span id="xdx_F0A_z5DIWog1rnph" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</span></td> <td style="width: 98%; text-align: justify"><span id="xdx_F1F_zd3ulVsxFroc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current or former officer or director or controlled entity by current or former officer or director</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"><span id="xdx_F01_zzYSgsAQhBl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</span></td> <td style="width: 98%; text-align: justify"><span id="xdx_F17_zBxOAR0tByMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative of former officer</span></td></tr> </table> <p id="xdx_8AA_zqnThooM1Zy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the listed loans indicated with an A are demand loans that have a one-year term and an auto renewal feature. They bear an interest rate of 10% per annum.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan indicated with a B does not have stated terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The entire balance of related party loans is recorded as current liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Total accrued interest on related party debts was $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyDebtsMember_ztfklsPQAEBd" title="Accrued interest">605,510</span> at March 31, 2026 and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyDebtsMember_zDLDggsDSXNg" title="Accrued interest">567,422</span> at December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zaQ8IJsF66Z4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOANS (Details - Loans from unrelated parties)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zaUZgj1iTKs5" style="display: none">Schedule of loans from unrelated parties</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">(A) Howard notes - In Default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--HowardNotesMember_zIbJIL2Jshy5" style="width: 13%; text-align: right" title="Loans from unrelated parties">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--HowardNotesMember_pp0p0" style="width: 13%; text-align: right" title="Loans from unrelated parties">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(B) Goff note - In Default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--GoffNoteMember_zeemO7Il7HDd" style="text-align: right" title="Loans from unrelated parties">22,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--GoffNoteMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">22,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">(C) Insurance notes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--InsuranceNotesMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">4,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceNotesMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">6,083</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(D) Alder note, net of discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--AlderNotesNetOfDiscountMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">263,767</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--AlderNotesNetOfDiscountMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">285,864</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">(E) EIDL notes ($400,000 in default)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LoansPayable_iI_pp0p0_c20260331__us-gaap--LongtermDebtTypeAxis__custom--EIDLNotesMember_zIxJl5xYy5Ab" style="text-align: right" title="Loans from unrelated parties">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--EIDLNotesMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">550,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(F) Stripe Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">22,729</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--StripeCapitalMember_pp0p0" style="text-align: right" title="Loans from unrelated parties">52,280</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">(G) Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--LoansPayable_c20260331__us-gaap--LongtermDebtTypeAxis__custom--OtherNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Loans from unrelated parties">171,510</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LoansPayable_c20251231__us-gaap--LongtermDebtTypeAxis__custom--OtherNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Loans from unrelated parties">168,304</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LoansPayable_c20260331_pp0p0" style="text-align: right" title="Loans from unrelated parties">1,135,179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LoansPayable_c20251231_pp0p0" style="text-align: right" title="Loans from unrelated parties">1,185,031</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LoansPayableCurrent_iNI_pp0p0_di_c20260331_zMtFi3l1qN9h" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(952,615</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LoansPayableCurrent_iNI_pp0p0_di_c20251231_zOHZEgVHrAd2" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(1,003,206</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total long term</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LongTermLoansPayable_c20260331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total long term">182,564</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LongTermLoansPayable_c20251231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total long term">181,825</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 100000 100000 22500 22500 4673 6083 263767 285864 550000 550000 22729 52280 171510 168304 1135179 1185031 952615 1003206 182564 181825 50000 165000 15000 72000 9990 49980 328644 295207 2000000 0.10 10000 0.1325 3000000 0.015 22097 550000 550000 150000 400000 200000 0.0375 105800 7935 0.07 29550 22729 160000 171510 168304 <table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfRelatdPartyDebtTableTextBlock_zTSsxVndJVH7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOANS (Details - Related party debt)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8BA_zMYEKaPk3O26" style="display: none">Schedule of related party debt</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Related Party</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2026</b></td><td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2025</b></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 61%; text-align: left">Libertas Trust</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertasTrustMember_fKEEp_z6McZJqPhRla" style="width: 13%; text-align: right" title="Note payable - related party">180,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertasTrustMember_fKEEp_zHWORrZdrMUk" style="width: 13%; text-align: right" title="Note payable - related party">180,000</td><td style="width: 1%; text-align: left"> </td> <td style="width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Wilshire Holding Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilshireHoldingTrustMember_fKEEp_zjXhnHLQyH38" style="text-align: right" title="Note payable - related party">518,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilshireHoldingTrustMember_fKEEp_zxZNxgyduVle" style="text-align: right" title="Note payable - related party">518,000</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Resco Enterprises Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RescoEnterprisesTrustMember_fKEEp_zEn1JoTJ9Aji" style="text-align: right" title="Note payable - related party">157,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RescoEnterprisesTrustMember_fKEEp_znH4nESW2Ygk" style="text-align: right" title="Note payable - related party">157,747</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Avis Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvisTrustMember_fKEEp_zznJ1Yxvv9Fb" style="text-align: right" title="Note payable - related party">67,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvisTrustMember_fKEEp_zWy1tOEwtLme" style="text-align: right" title="Note payable - related party">67,606</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">JS Bird</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JoesphBirdMember_fKEEp_z0leeczmL34b" style="text-align: right" title="Note payable - related party">32,079</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JoesphBirdMember_fKEEp_zDb4DtK86XEi" style="text-align: right" title="Note payable - related party">32,079</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thomas Power</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThomasPowerMember_fKEEp_zPWCcay0rjCi" style="text-align: right" title="Note payable - related party">34,899</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThomasPowerMember_fKEEp_z9cONgCldcG3" style="text-align: right" title="Note payable - related party">34,159</td><td style="text-align: left"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Richard Long</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RichardLongMember_fKEIp_zanDyAWwJB5b" style="border-bottom: Black 1pt solid; text-align: right" title="Note payable - related party">39,862</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_iI_pp0p0_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RichardLongMember_fKEIp_zsH5gKbkoUrl" style="border-bottom: Black 1pt solid; text-align: right" title="Note payable - related party">39,862</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_c20260331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable - related party">1,030,193</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NotesPayableAndLoansRelatedPartiesCurrent_c20251231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable - related party">1,029,453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"><span id="xdx_F0A_z5DIWog1rnph" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</span></td> <td style="width: 98%; text-align: justify"><span id="xdx_F1F_zd3ulVsxFroc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current or former officer or director or controlled entity by current or former officer or director</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"><span id="xdx_F01_zzYSgsAQhBl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</span></td> <td style="width: 98%; text-align: justify"><span id="xdx_F17_zBxOAR0tByMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative of former officer</span></td></tr> </table> 180000 180000 518000 518000 157747 157747 67606 67606 32079 32079 34899 34159 39862 39862 1030193 1029453 605510 567422 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zBUqWiQfGjSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 6 —<span id="xdx_825_zLGKQaMUmExa"> RELATED-PARTY TRANSACTIONS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company rents its home office from BBD Holdings, LLC which is controlled by Joseph Bird, an officer and director. The rental is on the month-to-month basis and is at a rate of $1,725 per month which is no more than the prevailing rate for the Chattanooga, TN market. Rent paid during the three months ended March 31, 2026 and 2025 were $<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_c20260101__20260331_zKGEThFo5tU7" title="Rent paid">5,175</span> and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20250101__20250331_zW85kBCKzrYl" title="Rent paid">5,175</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sells a product subject to a royalty agreement with the VHS Pool that was set up by a predecessor entity, through two of its subsidiaries. A former officer and director – Robert Long - through a related entity – Lone Peak Innovative Holdings, LLC, has a creditor interest in the VHS Pool. Lone Peak Innovative Holdings, LLC has to date not received payments from the VHS Pool and the likelihood of future payments is not ascertainable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The royalty agreement calls for the payment of 1% of the gross sales of the subject product(s). The royalty applies to any product designed to support a healthy Endothelium Glycocalyx, such as the company’s Endocalyx Pro product. The royalty agreement also calls for the payment of 1% of the proceeds, after taxes, on a liquidity event. A liquidity event is defined as the subsidiary entering an arms-length transaction with a third party or making an initial public offering. Should a liquidity even occur, the agreement requires a minimum payment to raise the pool amount to $7,500,000. The maximum amount of the VHS Pool is $15,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties incurred during the three months periods ending March 31, 2026 and 2025 were $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20260101__20260331_zPJf4A0FcrI3" title="Royalty expense">2,025</span> and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20250101__20250331_zYLEy5b3gdT5" title="Royalty expense">2,717</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Distribution Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a worldwide distribution agreement with GlycoCheck B.V. for the GlycoCheck machine distribution. Bob Long and Hans Vink are former officers and directors of BioRegenx, Inc., and were removed as directors of GlycoCheck B.V. during the quarter ended September 30, 2025. Mr. Long and Mr. Vink may have an ownership interest in Glycocheck B.V. There were no amounts paid or accrued under the distribution agreement during the three months ended March 31, 2026 and 2025. A cancellation notice was issued in January of 2024 without the consent of the majority owners of GlycoCheck B.V. In November 2023, GlycoCheck B.V. lost its license to use the technology, which was the basis of the distribution agreement with the Company. The licensor of the technology is an unrelated party and has allowed the Company to continue to operate under the terms of the original agreement. In May of 2025 the Company acquired the rights to the technology to which the distribution agreement was based.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal Counsel</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s legal counselors included a former member of the board of directors, Jody Walker. Jody provided legal services for SEC reporting and general legal matters through her firm J.W. Walker &amp; Associates until her resignation in July of 2024. The balance of $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_c20260331__srt--CounterpartyNameAxis__custom--JodyWalkerMember_zasMAlMieKE2" title="Notes balance">72,061</span> was still owed by the Company as of March 31, 2026. <span id="xdx_901_eus-gaap--LegalFees_do_c20260101__20260331_zu4kluqUmGcf" title="Legal fees"><span id="xdx_909_eus-gaap--LegalFees_do_c20250101__20250331_zjgidpDOZsng" title="Legal fees">No</span></span> legal fees were incurred or paid during three month periods ended March 31, 2026 and 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Accounts Payable – Related Parties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reimburses certain officers and board members for company expenses paid through individual credit cards. Total short-term advances from Resides Enterprises, a company controlled by William Resides, Chief Executive Officer, were $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResidesEnterprisesMember_z1J0KJxtZ40f" title="Proceeds from related party">169,666</span> at March 31, 2026, and $<span id="xdx_90D_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResidesEnterprisesMember_zjGUPiquNJEi" title="Proceeds from related party">268,545</span> at December 31, 2025, from Thomas Power were $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThomasPowerMember_z0C9B7W1m8U4" title="Proceeds from related party">55,750</span> at March 31, 2026, and $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThomasPowerMember_zlywWENnGQjc" title="Proceeds from related party">54,250</span> at December 31, 2025 and from Gary Hennerberg were $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GaryHennerbergMember_zLRowP0Jo8ke" title="Proceeds from related party">22,725</span> at March 31, 2026, and $<span id="xdx_904_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GaryHennerbergMember_zZhijAW25cji" title="Proceeds from related party">23,845</span> at December 31, 2025. Balances due to prior officers and board members were $<span id="xdx_901_ecustom--AccountPayableRelatedPartiesCurrent_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PriorOfficersAndBoardMembersMember_pp0p0" title="Accounts payable - related parties">9,107</span> at March 31, 2026 and $<span id="xdx_900_ecustom--AccountPayableRelatedPartiesCurrent_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PriorOfficersAndBoardMembersMember_pp0p0" title="Accounts payable - related parties">9,107</span> at December 31, 2025. The amounts due are unsecured, do not have stated interest, with no formal terms of repayment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Notes Payable – Related Parties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain related party loans are secured by all assets of the Company or all assets of a subsidiary as evidenced by UCC Financing Statements as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zajWkdCxaQ5a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED-PARTY TRANSACTIONS (Details - Notes payable- related party parties)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BD_zEcKqSgUEIQ" style="display: none">Schedule of secured related party loans</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed on Loans to BioRegenx:</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Libertas Trust</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_ecustom--RelatedPartyLoan_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BioregenxMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertasTrustMember_zoP7LhXUm95a" style="width: 13%; text-align: right" title="Related party loan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180,000</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilshire Holding Trust</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_ecustom--RelatedPartyLoan_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BioregenxMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilshireHoldingTrustMember_pp0p0" style="text-align: right" title="Related party loan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">518,000</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED-PARTY TRANSACTIONS (Details - Notes payable- related party parties)"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed on Loans to NuLife Sciences:</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resco Enterprises Trust</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_ecustom--RelatedPartyLoan_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--NuLifeSciencesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RescoEnterprisesTrustMember_pp0p0" style="width: 13%; text-align: right" title="Related party loan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,747</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avis Trust</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_980_ecustom--RelatedPartyLoan_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--NuLifeSciencesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvisTrustMember_pp0p0" style="text-align: right" title="Related party loan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,606</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 5175 5175 2025 2717 72061 0 0 169666 268545 55750 54250 22725 23845 9107 9107 <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zajWkdCxaQ5a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED-PARTY TRANSACTIONS (Details - Notes payable- related party parties)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BD_zEcKqSgUEIQ" style="display: none">Schedule of secured related party loans</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed on Loans to BioRegenx:</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Libertas Trust</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_ecustom--RelatedPartyLoan_iI_pp0p0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BioregenxMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertasTrustMember_zoP7LhXUm95a" style="width: 13%; text-align: right" title="Related party loan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180,000</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilshire Holding Trust</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_ecustom--RelatedPartyLoan_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--BioregenxMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilshireHoldingTrustMember_pp0p0" style="text-align: right" title="Related party loan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">518,000</span></td> <td> </td></tr> </table> 180000 518000 157747 67606 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zW6qyRihmxSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 7 — <span id="xdx_829_zbBup9wNERT9">COMMITMENTS AND CONTINGENCIES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Lease Commitments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases office space for its headquarters in Chattanooga Tennessee under a short-term lease. The headquarters is leased from a related party on a month-to-month basis for $1,725 per month. In addition, the Company also rents storage space on a month-to-month basis in various locations with total monthly cost of less than $1,000 per month. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Warrants issuable upon financing</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2023, Hitesh Juneja, a former employee, was granted warrants in an amount to be determined based on the amount of approved equity financing related to his efforts. The grant provided for warrants equal to ½% of the outstanding shares at the time of the grant. Warrants for the ½% of outstanding shares would be issued for bringing in $1,000,000 of equity, with a maximum percentage of 7% for larger equity fundings. The warrants would be exercisable at the fair market value of the shares on the date of funding. The warrants are exercisable one third on the date of grant and one third each of the next two years. No warrants have been issued under this grant and no compensation expense has been recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>VHS Pool</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January of 2025, a member of the VHS Pool contacted the Company and claimed the change in ownership of Microvascular Health Solutions when it became a subsidiary of the Company in April of 2021 may potentially constitute a liquidity event which would accelerate the VHS Pool payments. The Company and the VHS Pool Member have since been negotiating terms of a revised royalty agreement. The parties agreed to a tolling of the statute of limitations of the potential breach until the earlier of March 31, 2026 or within in 60 days after either party terminate the agreement. In February 2026,the tolling agreement was extended until March 31, 2027, or within in 60 days after either party terminate the agreement. The Company does not believe there has been a breach and that the effect of a revised agreement will not have a material effect on the financial statements or future operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>GlycoCheck B.V. Lawsuit</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2025, former officers and directors of the Company, Bob Long and Hans Vink, in their capacity as directors of GlycoCheck B.V. (“GlycoCheck”), filed a complaint against the Company and its subsidiary, MicroVascular Health Solutions, LLC, in the Business and Chancery Court of the State of Utah, alleging breach of contract and related damages resulting from unpaid royalties and unjust enrichment. The plaintiffs claimed damages in excess of $566,682. The Company evaluated the claims and considers them to be without merit, based on the following reasons; (1) in November 2023, GlycoCheck lost its license to use the technology, which was the basis of the contract that is the subject of the claim, (2) the licensor of the technology is an unrelated party and has allowed the Company to continue to operate under the terms of the original agreement and (3) there were no amounts paid or accrued under the contract during the years ended December 31, 2025 and 2024. During the quarter ended September 30, 2025, Bob Long and Hans Vink were removed as directors of GlycoCheck B.V. and the suit was dismissed by the current directors of GlycoCheck B.V.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>BioRegenx Action Against Former Officers and Affiliated Entities</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2025, the Company filed an action against Bob Long, Hans Vink and related companies seeking injunctive relief and asserting claims relating to intellectual property and breach of contract. As of the date of this report, the matter remains pending. While management cannot predict the outcome with certainty, the Company intends to pursue the action vigorously. No amounts have been accrued or recognized as a gain contingency in the accompanying condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Company disputes and other claims</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is involved in disputes with certain parties, including parties that are former officers and board members and vendors associated with their activities and contractual issues. Such disputes arise from time to time in the ordinary course of conducting business. The disputes including matters involving amounts due to the Company, contract performance standards, options and warrants granted and liabilities under contracts or arrangements entered by the prior officers including with parties related to them. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While assurance cannot be given as to the outcome of these disputes, management does not currently believe that any of these matters, individually or in the aggregate are estimable or probable and is therefore unable to represent whether they would have a material adverse effect on the Company’s financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zePaakLVOsZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 8— <span id="xdx_82D_zOKgm3pmAvUa">SEGMENT INFORMATION</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company operates and manages its business as <span id="xdx_900_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20260101__20260331_z2Zz2AITRMHk" title="Number of reportable segment::XDX::1"><span id="xdx_90C_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20260101__20260331_zRslig9JnQXf" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0925"><span style="-sec-ix-hidden: xdx2ixbrl0927">one</span></span></span></span> reportable and operating segment as a medical testing, diagnostic and nutraceutical company. The Company focuses on commercialization of its patented technologies in its field. The primary measure of segment profit or loss reviewed by the CODM is consolidated net loss. The CODM also reviews gross sales and cost of goods sold as key performance indicators. CODM includes financing costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s Chief Operating Decision Maker (CODM) reviews financial information and presented and decides how to allocate resources based on potential new revenues. gross sales, cost of goods sold and net income (loss) are used for evaluating financial performance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant segment items used by the CODM include gross sales, cost of goods sold, salaries, stock-based compensation, distributor incentive, legal and accounting, depreciation and amortization and interest expense.</p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0fuLXRYE9ej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details - segment information)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B9_zKKfba1EsZDb" style="display: none">Schedule of segment reporting</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20260101__20260331_zi3jBiizkBA" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20250101__20250331_zlyK0kmMziX7" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_zc3rOygSIC6h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Sales </b></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">426,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">515,147</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CostOfRevenue_z6YJSTteCEDj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Cost of goods sold</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,887</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--SalariesAndWages_zP3CLnCy2WRi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Salaries and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,220</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ShareBasedCompensation1_zlOQCC5fl1zj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,633</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncentiveFeeExpense_zas9IT60fk7f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Distributors incentives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,658</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,278</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ProfessionalFees_zxBYpX1MYfT" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Legal and accounting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherDepreciationAndAmortization_zI77sBvVQQEj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,377</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherGeneralExpense_zA9fLsbEuzT5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Other operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">284,229</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_zA93jIwtEBwe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,086</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74,239</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherIncome_d0_z1viZM1C2uF7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">100,435</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zFM5v1OOxRl6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26,415</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(266,854</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0fuLXRYE9ej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details - segment information)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B9_zKKfba1EsZDb" style="display: none">Schedule of segment reporting</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20260101__20260331_zi3jBiizkBA" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20250101__20250331_zlyK0kmMziX7" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_zc3rOygSIC6h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Sales </b></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">426,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">515,147</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CostOfRevenue_z6YJSTteCEDj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Cost of goods sold</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,887</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--SalariesAndWages_zP3CLnCy2WRi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Salaries and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,220</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ShareBasedCompensation1_zlOQCC5fl1zj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,633</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncentiveFeeExpense_zas9IT60fk7f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Distributors incentives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,658</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,278</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ProfessionalFees_zxBYpX1MYfT" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Legal and accounting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherDepreciationAndAmortization_zI77sBvVQQEj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,377</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherGeneralExpense_zA9fLsbEuzT5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Other operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">284,229</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_zA93jIwtEBwe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,086</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74,239</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherIncome_d0_z1viZM1C2uF7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">100,435</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zFM5v1OOxRl6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26,415</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(266,854</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 426175 515147 77887 109116 79198 98220 30353 75633 1658 8278 83569 119909 12943 12377 190331 284229 77086 74239 100435 0 -26415 -266854 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJCGtb3BpzBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 9 —<span id="xdx_82D_zgeqS4V5igpi">SUBSEQUENT EVENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through the date the consolidated financial statements were issued. Subsequent to March 31, 2026, the Company continued to pursue financing alternatives and continued to receive advances from related parties to support operations. No other subsequent events occurred that would require adjustment to or additional disclosure in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> false false false false Current or former officer or director or controlled entity by current or former officer or director Relative of former officer